|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 23, 2016 ) The Breast Cancer Therapeutics Market Report shows that the number of women diagnosed with breast cancer has increased over the past few decades, but the number of deaths has declined due to earlier diagnosis and better treatment options. Breast cancer treatment has been revolutionized in the past four decades, especially with increasing usage of targeted therapies. The marketed products landscape comprises a wide range of treatment options, including hormonal therapies, chemotherapies, combination therapies, and targeted therapies. Nevertheless, significant unmet need remains for products that can improve overall survival rate, time to disease progression, and overall response.
Other Key Points in Report:
The current breast cancer market contains novel products, including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent.
-What are the competitive advantages of the existing novel drugs?
With over 700 active pipeline molecules, most of the investigational drug candidates are being evaluated for the first-line or second-line treatment of advanced-stage breast cancer, featuring new combination therapies, targeted therapies, and promising immunotherapies, as well as chemotherapy drug candidates.
-Which classes of novel drugs are most prominent within the pipeline?
-Is there strong potential for the pipeline to address unmet needs within the breast cancer market?
Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II (41%), with the overall attrition rate for breast cancer in development being 61%.
-How do failure rates vary by product stage of development, molecule type, and mechanism of action?
-How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?
Over the 2014-2021 forecast period, the breast cancer therapeutics market in the eight major markets is expected to increase in value at a CAGR of 7.3%, from $10.4 billion to over $17.2 billion.
-Which markets make the most significant contribution to the current market size?
-What are the epidemiology trends in these markets?
-Will new market entrants lead to substantial changes in annual therapy costs?
-How will different treatment usage patterns impact growth in the eight major markets?
Inquire before Buying Report@ http://www.reportsweb.com/inquiry&RW0001170040/buying
Table of Content: An Overview
2 Introduction 9
2.1 Disease Introduction 9
2.2 Symptoms 10
2.3 Etiology 10
2.4 Pathophysiology 11
2.5 Epidemiology 12
2.6 Diagnosis and Classification 14
2.7 Prognosis and Disease Staging 15
2.8 Treatment Options 17
2.8.1 Surgery and Radiation Therapy 18
2.8.2 Chemotherapy 18
2.8.3 Hormonal Therapies 19
2.8.4 Targeted Therapies 20
2.8.5 Resistance to Pharmacological Therapies 20
2.9 Treatment Guidelines 21
3 Marketed Products 24
3.1 Overview 24
3.1.1 Herceptin (trastuzumab)-Genentech 24
3.1.2 Perjeta (pertuzumab)-Genentech 26
3.1.3 Afinitor (everolimus)-Novartis 27
3.1.4 Tykerb/ Tyverb (lapatinib ditosylate monohydrate)-Novartis 28
3.1.5 Ibrance (palbociclib)-Pfizer 29
3.1.6 Ixempra (ixabepilone)-Bristol-Myers Squibb 29
3.1.7 Halaven (eribulin mesylate)-Eisai 30
3.1.8 Avastin (bevacizumab)-Genentech 31
3.1.9 Kadcyla (ado-trastuzumab emtansine)-Genentech 31
3.1.10 Marketed Products Heatmap 32
3.1.11 Measuring the Effectiveness of Treatment 38
3.2 Conclusion 39
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001170040/discount
4 Pipeline Products 40
4.1 Pipeline Products 40
4.1.1 Overall Pipeline 40
4.1.2 Pipeline by Molecular Target 41
4.2 Clinical Trials 44
4.2.1 Failure Rate 44
4.2.2 Patient Enrollment and Clinical Trial Size 46
4.2.3 Duration 50
4.3 Competitive Clinical Trials Metrics Analysis 52
5 Promising Drug Candidates in Pipeline 54
5.1 Abemaciclib-Eli Lily 54
5.1.1 Abemaciclib Forecast 54
5.2 Buparlisib-Novartis 55
5.2.1 Buparlisib Forecast 56
5.3 NeuVax (nelipepimut-S)-Galena Biopharma 56
5.3.1 NeuVax Forecast 57
5.4 Niraparib-Tesaro 57
5.4.1 Niraparib Forecast 58
5.5 Lynparza (Olaparib)-AstraZeneca 58
5.5.1 Lynparza Forecast 59
5.6 Veliparib-AbbVie 60
5.6.1 Veliparib Forecast 60
5.7 Neratinib-Puma Biotechnology 61
5.7.1 Neratinib Forecast 62
5.8 Ribociclib-Novartis 62
5.8.1 Ribociclib Forecast 63
5.9 Talazoparib-BioMarin 64
5.10 Alpelisib-Novartis 64
5.11 Atezolizumab-Roche 65
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001170040/buy/4995
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
